No significant differences in CD8+ NK levels were observed between the tumor molecular subtype in DLBCL (GCB and no GCB by Hans algorithm), or between patients with or without refractory disease (Supplementary Figure 3). The gene discussed is CD8A; the disease is neoplasm.